NKN. N. Kasatkina

N. N. Kasatkina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


N. N. Kasatkina has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phytocomponents screening for oncoprotector development

    by O. A. Bocharova, A. A. Aksyonov, R. V. Karpova, E. V. Bocharov, N. N. Kasatkina, I. V. Kazeev, M. V. Utkina, V. G. Kucheryanu, V. S. Kosorukov, I. S. Stilidi

    Background. Medicinal plants have a high chemopreventive potential in oncology. The structural diversity of plant biologically active substances: phenolic compounds (simple phenols, flavonoids, phenolic acids, tannins, etc.), terpenoids (mono-, diterpenoids, triterpene saponins, etc.), essential oils, for example, results in a wide range of antitumor activity. Complex herbal preparations are more effective and safe due to their multi-target effects on various regulatory mechanisms in combination with relatively low toxicity. The development of effective natural pharmaceutical compositions based on the structural diversity of biologically active substances seems relevant.Aim. Number plant extracts antiproliferative effect against CaOv human ovarian adenocarcinoma cells investigation and potential phytocomponents selection for the novel antitumor pharmaceutical composition development.Materials and methods. CaOv human ovarian adenocarcinoma cell line was used as a test model. The antiproliferative effect of plant extracts was measured by the radiometric method based on the 3H-thymidine incorporation into CaOv cells DNA. Half maximal inhibitory concentration (IC50) was calculated using probit analysis. The selection of vegetable oil as an optimal extraction agent was carried out on C57BL/6 male mice based on the wound healing effect.Results. The antiproliferative activity of 27 medical plant extracts was studied. The 14 most effective ones in these conditions were selected based on the IC50. Linseed oil was chosen as an optimal extraction agent considered the wound-healing effect of individual vegetable oils (linseed, sunflower, corn), as well as the corresponding oil extracts of the phytocomposition.Conclusion. The selected phytocomponents can be used as a foundation for an optimal compound development of a new pharmaceutical composition aimed at chemoprevention in cancer care. The choice of linseed vegetable oil as an experimental phytocomposition extractant is justified.

  • Open Access

    Comparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders

    by L. A. Kesaeva, A. Yu. Bulanov, Yu. P. Finashutina, V. V. Tikhonova, O. N. Solopova, E. N. Misyurina, N. N. Kasatkina, N. A. Lyzhko, V. A. Misyurin, A. A. Turba, et al.

    Molecular genetic detection of CALR gene somatic mutations is required for myeloproliferative neoplasms diagnosis and treatment according to the novel WHO clinical recommendations. CALR mutations are found in approximately 25–35 % cases of essential thrombocythemia and primary myelofibrosis and they are associated with benign clinical outcome. In this study we have compared sensitivity and selectivity of seve ral different options of CALR mutation molecular genetic detection in blood samples of 379 CMD patients and 17 healthy donors. Among methods compared in our study there have been conventional polymerase chain reaction with electrophoretic detection, real-time quantitative polymerase chain reaction, direct Sanger sequencing of polymerase chain reaction fragments and polymerase chain reaction high resolution melting curve analysis. By means of melting curve analysis CALR mutations have been found in 97 (25.5 %) patients, whereas in the cases of Sanger sequencing and polymerase chain reaction there have been 87 (23.0 %) and 84 (22.1 %) CALR mutation positive patients respectively.

  • Open Access

    Complex cytogenetic research of cryptic chromosomal aberrations in patients with multiple myeloma

    by A. A. Solodovnik, А. S. Mkrtchyan, V. A. Misyurin, L. A. Kesaeva, N. N. Kasatkina, O. M. Votyakova, O. Yu. Yakimovich, E. G. Medvedovskaya, A. S. Antipova, I. Z. Zavodnova, et al.

    Background . Multiple myeloma (MM) is a malignant lymphoproliferative B-cell disease characterization by clonal proliferation of plasma cells in the bone marrow and beyond its borders. Currently, a wide range of cytogenetic anomalies and molecular-biological parameters are studied as prognostic factors.Objective: a comparative study of the frequency, features and clinical significance of chromosomal abnormalities in MM by conventional cytogenetic and fluorescent in situ hybridization (FISH) methods.Materials and methods . 77 patients with MM, which admitted in N.N. Blokhin National Medical Research Center of Oncology, were included in the study from 2016 to 2017.Results . Chromosomal alterations were detected only in one case (1/77) by conventional cytogenetic method G-banding. However cytogenetic aberrations were revealed in 26 % of cases (20/77) using FISH. Deletions of different regions of chromosomes, indicating the possible presence of a hypodiploid clone or loss of some regions, were found in one patient in the second FISH analysis after 6 months. In the cohort of patients with chromosomal abnormalities (n = 20) a partial trisomy 11q, a deletion of the region q32 of the chromosome 14, a translocation t(4;14)(p16;q32) and IGHV gene rearrangement were determined in 30 % (6/20) as sole anomalies. Two or more cytogenetic aberrations were identified in the remaining 14 patients. Our study confirms that chromosomal abnormalities are more likely detected at later stages of MM (IA и IIA – 0 %, IIIA и IIIВ – 27 and 47 % respectively).Conclusion . FISH allows to detect chromosomal changes in tumor plasma cells regardless of the mitosis phase. In MM, it becomes particularly important in connection with low proliferative activity of plasma cells. Additionally, in the fourth of MM patients in the study submicroscopic chromosomal aberrations were discovered using FISH. The improvement of the probe panel and the widespread use of locus specific FISH don’t replace G-banding that allows to see damages of all chromosomes at once.


  • Open Access

    EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE

    by A. A. Solodovnik, H. S. Mkrtchyan, V. A. Misyurin, V. V. Tikhonova, Yu. P. Finashutina, N. N. Kasatkina, O. N. Solopova, O. M. Votyakova, O. Yu. Yakimovich, O. M. Volodina, et al.

    Objective: to study the prognostic significance of the expression of cancer-testis (CT) genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 in patients with multiple myeloma (MM) and their influence on overall survival and relapse rate. To determine their effect on suсh clinical parameters as levels of lactate dehydrogenase, leucocytes, hemoglobin, calcium, albumen, creatinine, beta-2-microglobulin.Materials and methods. Real-time polymerase chain reaction was performed on complementary DNA obtained from bone marrow of 77 patients with MM. The statistical analysis was performed using the Statistica 10.0 software package. To estimate prognostic values of the CT gene expression data were analyzed by the Kaplan – Meier method.Results. The study was conducted to determine the level of expression of CT genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 in a group of patients with MM. The group included primary and receiving cancer treatment in MM patients. According to the log-rank criterion expression of any of the CT genes PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 exerts a significant influence on overall survival and progression-free survival/relapse. It was also determined that providing expression of some CT genes, the levels of creatinine, calcium, beta-2-microglobulin were much higher to compare with patients without expression.